Pular para o conteúdo
Case de Valor
Voltar para Stocks
BSX

BSX

Boston Scientific Corporation

NYSE / NasdaqSaúde
Fechamento (EOD)
US$ 45,69-0,70%

Indicadores principais

Valuation

Valor de Mercado

US$ 66,2 Bi

Da companhia, em dólares

Valuation

P/L

18,5×

Preço / Lucro

Valuation

P/L Futuro

13,5×

Sobre o lucro projetado pelo consenso

Valuation

P/VP

2,7×

Preço / Valor Patr.

Rentabilidade

Margem Líquida

17,5%

Parcela da receita convertida em lucro líquido.

Rentabilidade

ROE

15,3%

Retorno s/ patrimônio

Rentabilidade

Dividend Yield

—

Último provento anualizado

Setor

Saúde

Medical Devices

Histórico de Preço

US$ 45,69

Performance

1 dia

—

1 sem

—

1 mês

—

3 meses

—

6 meses

—

1 ano

—

5 anos

—

Dados gerais

SetorSaúde
IndústriaMedical Devices
PaísEstados Unidos
Funcionários59.000
MoedaUSD

Descrição

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Cotação com possível atraso. Conteúdo de caráter informativo e educacional. Não constitui recomendação de compra, venda ou manutenção de ativos.